Faes Farma (FAE.MC) Aktie Kurs
Faes Farma Kurs
De seneste 19 år voksede Faes Farmas omsætning med 6,5 % årligt og nåede 610,46 Mio. EUR. Indtjening pr. aktie er vokset med 6,8 % om året de seneste 19 år. For Faes Farma er nettoavance på 13,0 % ned i forhold til 20,7 % for et par år siden. Ved dagens kurs bliver direkteafkastet cirka 3,54 %. Udlodningsandelen er omkring 70 % af indtjeningen. Udbyttet er vokset med 5,5 % om året de seneste 19 år. Konsensus 12-måneders kursmål for Faes Farma er 5,61 EUR, cirka over kursen med 10,9 %. Af 10 analytikere anbefaler 6 køb — den samlede vurdering er Køb.
Faes Farma aktiekurs
Hent disse data via Eulerpool API
100.000 requests/md. gratis · intet kreditkort
Faes Farma aktie og aktieanalyse
Hyppigt stillede spørgsmål om Faes Farma-aktien
The business model of Faes Farma SA is focused on the research, development, manufacture, and commercialization of pharmaceutical products. The company specializes in the areas of prescription drugs, hospital medications, and non-prescription drugs. Faes Farma SA operates through a diversified portfolio, catering to various therapeutic areas such as respiratory, dermatology, allergy, and gastrointestinal disorders. The company aims to provide innovative and effective solutions to improve people's health and quality of life. Faes Farma SA's commitment to scientific excellence, strategic partnerships, and continuous product development enables it to meet the evolving needs of patients worldwide.
Faes Farma SA is primarily active in the pharmaceutical industry.
Some of the main competitors of Faes Farma SA in the market include pharmaceutical companies like Grupo Ferrer Internacional, Laboratorios Rubió, Almirall, and Laboratorios Normon.
Faes Farma SA is a leading pharmaceutical company with a rich history and strong background. Established in 1933, Faes Farma has grown steadily over the years to become a key player in the healthcare industry. The company specializes in the research, development, manufacturing, and commercialization of innovative drugs and health products. With a primary focus on respiratory, allergy, and anti-inflammatory treatments, Faes Farma has built a solid reputation for delivering high-quality and effective pharmaceutical solutions. Through continuous innovation and strategic partnerships, the company has successfully expanded its global presence and has become a trusted name in the pharmaceutical sector.
Faes Farma SA, a leading pharmaceutical company, has achieved several significant milestones throughout its history. One notable milestone is the successful development and commercialization of innovative pharmaceutical products. The company has also expanded its market reach globally, establishing a strong presence in various countries. Furthermore, Faes Farma SA has demonstrated continuous growth through strategic partnerships, collaborations, and acquisitions. These milestones reflect the company's commitment to advancing healthcare and delivering quality solutions to customers worldwide. With its relentless dedication and industry expertise, Faes Farma SA has emerged as a prominent player in the pharmaceutical sector, consistently achieving commendable results.
Faes Farma SA is primarily present in Spain and Portugal.
Faes Farma SA represents values and a corporate philosophy centered on innovation, excellence, and commitment to improving healthcare. With a focus on research and development, the company strives to develop high-quality pharmaceutical products that address unmet medical needs. With a long history dating back to 1933, Faes Farma SA emphasizes ethical business practices and sustainable growth. By leveraging its scientific expertise and state-of-the-art technologies, the company aims to provide effective therapies and contribute to the well-being of patients worldwide. Faes Farma SA's dedication to innovation and patient-centric approach makes it a reputable player in the pharmaceutical industry.
Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 5,36 EUR for Faes Farma-aktien (median: 5,61 EUR), svarende til +5,8 % i forhold til seneste kurs. Konsensus bygger på 10 analytikervurderinger.
10 analytikere vurderer i øjeblikket Faes Farma-aktien: 6 anbefaler køb, 3 hold og 1 salg. For 2026 forventer analytikere, at Faes Farma genererer omsætning på 739,60 Mio. EUR og indtjening pr. aktie på 0,29 EUR.
Faes Farma-aktien (FAE.MC) er noteret på 7 børser, herunder: London (0K9H.L), Frankfurt (FFEA.F), München (FFEA.MU), Düsseldorf (FFEA.DU), Madrid (FAE.MC).
Faes Farma SA is a leading pharmaceutical company specializing in the manufacturing and marketing of medicines and medical products. The company was founded in 1933 and is headquartered in Barcelona, Spain. Faes Farma operates in various business areas, including pharmaceutical products, diagnostic and laboratory services, and skincare products. Pharmaceutical products Faes Farma offers a wide range of pharmaceutical products that can be used to treat various diseases and ailments. The company focuses on the development of drugs in the areas of pain medicine, allergology, and respiratory and eye diseases. One outstanding product is Bilastine, an antihistamine used to treat allergic diseases. In 2020, the company generated sales of €136 million with Bilastine. Diagnostic and laboratory services Faes Farma also operates a division for diagnostic and laboratory services. The company offers various tests to detect and treat diseases early. For example, Faes Farma offers a test to determine if a person is suffering from celiac disease. Another example is a test that detects the presence of antibodies against SARS-CoV-2. Skincare products The company also offers a line of skincare products marketed under the brand Bionike. These products have been specifically developed for people with sensitive skin and do not contain questionable ingredients. The product range includes face creams, cleansers, and sunscreens. Faes Farma has a diversified business model based on the development of new products and the expansion into new markets. The company is focused on innovation and invests a significant portion of its sales in research and development every year. Thanks to its innovative capacity and strong market presence, Faes Farma has experienced solid growth in recent years. In 2020, the company had sales of €317.2 million. The size of the company allows for international business expansion. Faes Farma operates in over 80 countries and has a strong presence, particularly in Latin America and Asia.
forventet-omsætningen for Faes Farma er 739,60 Mio. EUR. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.
forventet-overskuddet for Faes Farma er 89,39 Mio. EUR. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.
Pris-til-indtjening-forholdet (P/E) for Faes Farma er i øjeblikket 17,62. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Faes Farma-aktien.
Pris-til-salgs-forholdet (P/S) for Faes Farma er i øjeblikket 2,13. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Faes Farma-aktien.
AlleAktien-kvalitetsscore for Faes Farma er 7/10.
ISIN for Faes Farma er ES0134950F36. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.
WKN for Faes Farma er A0MKAC. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.
Tickeren for Faes Farma er FAE.MC. Tickersymbolet bruges til at handle Faes Farma-aktier på børsen.
Faes Farma aktie
Faes Farma Peer Group
Faes Farma Ticker
Faes Farma FIGI
Alle fundamentale data om Faes Farma i deep dive
Vores aktieanalyse af Faes Farma-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos Faes Farma. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser: